Starpharma Holdings Ltd
(OTCQX: SPHRY)
|
3:14 PM UTC, 06/21/24 | |||
---|---|---|---|---|
Last: $0.63 | Change: -0.03 | %Change: -4.58% | Volume: 2,000 |
Open: | $ 0.63 | Volume: | 2,000 | |
---|---|---|---|---|
High: | $ 0.63 | Yield(%) | 0.00 | |
Low: | $ 0.63 | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | 25.55M | |
EPS ($) | n/a | Shares Out: | 41.20M |
% Price Change (last 4 weeks): | -6.77 |
---|---|
% Price Change (last 13 weeks): | -26.80 |
% Price Change (last 26 weeks): | -47.68 |
% Price Change (last 52 weeks): | -70.08 |
% Price Change (year to date): | -46.55 |
Return on Equity (%): | -37.27 |
---|---|
Return on Assets (%): | -26.24 |
Return on Invested Capital (%): | -35.21 |
Gross Profit Margin (%): | 41.60 |
---|---|
Net Profit Margin (%): | -532.09 |
Operating Profit Margin (%): | -839.50 |
|
|
50-day Moving Average: | $0.76 |
---|---|
200-day Moving Average: | $n/a |
Avg. Daily Vol. (last 50 days): | 2,758 |
Avg. Daily Vol. (last 200 days): | n/a |
52-wk high: | $2.81 |
52-wk low: | $0.63 |
Bid: | $n/a |
Ask: | $n/a |
Starpharma Holdings Ltd. engages in the research and development of dendrimer products for pharmaceutical, life science and other applications. The firm's programs include: VivaGel portfolio, Drug delivery and Agrochemicals, which develops a number of products internally and others via commercial partnerships. Its product VivaGel, a gel-based formulation of a proprietary dendrimer and is under clinical development for the treatment and prevention of bacterial vaginosis and also as a vaginal microbicide to prevent the transmission of sexually transmitted infections including HIV and genital herpes. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
|
Starpharma Holdings Ltd
4-6 Southampton Crescent Abbotsford VI 3067 Phone: 61.3.8532.2700 Fax: 61.3.9510.5955 http://www.starpharma.com |
Earnings (1year) ($): | -0.14 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 0.56 |
Cash Flow ($): | -0.24 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | 42.71 |
Price/Book (x): | 3.66 |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 3.06 |
---|---|
Current Ratio (x): | 3.26 |
LT Debt/Equity (x): | 7.90 |
Total Debt/Equity (x): | 23.76 |